RELISTOR

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Croatia, Cyprus, Estonia, Finland, France, Ireland, Italy, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Spain, UK.

Active ingredients

The drug RELISTOR contains one active pharmaceutical ingredient (API):

1	Methylnaltrexone UNII RFO6IL3D3M - METHYLNALTREXONE BROMIDE
	Methylnaltrexone bromide is a selective antagonist of opioid binding at the mu-receptor. As a quaternary amine, the ability of methylnaltrexone bromide to cross the blood-brain barrier is restricted. This allows methylnaltrexone bromide to function as a peripherally acting mu-opioid antagonist in tissues such as the gastrointestinal tract, without impacting opioid-mediated analgesic effects on the central nervous system.
	Read more about Methylnaltrexone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RELISTOR Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A06AH01	Methylnaltrexone	A Alimentary tract and metabolism → A06 Laxatives → A06A Laxatives → A06AH Peripheral opioid receptor antagonists
Discover more medicines within A06AH01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	5423K, 5424L
CA	Health Products and Food Branch	02308215
EE	Ravimiamet	1345878, 1348433, 1361696, 1493850, 1493861, 1493872, 1493883, 1493894, 1493906, 1493917, 1493928
ES	Centro de información online de medicamentos de la AEMPS	08463001, 08463003
FI	Lääkealan turvallisuus- ja kehittämiskeskus	453862, 503645
FR	Base de données publique des médicaments	60594326
GB	Medicines & Healthcare Products Regulatory Agency	137996, 137997
IE	Health Products Regulatory Authority	43711, 43734
IT	Agenzia del Farmaco	038600019, 038600021, 038600033
LT	Valstybinė vaistų kontrolės tarnyba	1033291, 1033292, 1033293, 1056507, 1056508, 1056509, 1056510, 1056511, 1056512, 1056513, 1056514
NL	Z-Index G-Standaard, PRK	86754
NZ	Medicines and Medical Devices Safety Authority	16300
PL	Rejestru Produktów Leczniczych	100198105, 100235958, 100235964
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W53320001, W53320002, W53320003
SG	Health Sciences Authority	13783P
US	FDA, National Drug Code	65649-150, 65649-551